Lead Program Centauri Therapeutics is advancing CTX-187 towards Phase I and has a notable ABX-01 antimicrobial program, presenting primary outreach opportunities to potential collaboration, licensing, or funding partners in early clinical development and antimicrobial resistance spaces.

AI Immunity Alphamer platform enables programmable immunity by redirecting existing antibodies to pathogens, indicating potential partnerships with biotech firms seeking novel immunotherapy mechanisms, platform licensing discussions, or joint development with academic collaborators.

Funding Momentum Recent Series A extensions and substantial AMR Action Fund support imply strong investor and strategic interest; explore co-development, milestone-based deals, or bridge funding conversations to accelerate late-stage progression.

Clinical & IP Robust IP and a growing lead portfolio combined with a high-priority clinical candidate slate suggest opportunities for strategic licensing, research collaborations, or contract research services to de-risk early-phase programs.

Market Readiness Broad-spectrum antimicrobial focus aligned with drug-resistant bacteria and hospital/clinical settings indicates sales potential with hospital systems, stewardship programs, and public health initiatives seeking innovative antimicrobial solutions.